Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul L Chazot

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Drug News & Perspectives|April 7, 2010
Therapeutic potential of histamine H3 receptor antagonists in dementiasPaul L Chazot
British Journal of Pharmacology|May 6, 2009
Advances in histamine pharmacology reveal new drug targetsPaul L Chazot
Current Medicinal Chemistry|February 18, 2004
The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologiesPaul L Chazot
Current Opinion in Investigational Drugs (London, England : 2000)|July 31, 2007
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndromePaul L Chazot
British Journal of Pharmacology|August 16, 2013
Histamine pharmacology: four years onPaul L Chazot
Pharmacology Research & Perspectives|April 13, 2016
Preclinical animal anxiety research - flaws and prejudicesAbdelkader Ennaceur, Paul L Chazot
British Journal of Pharmacology|January 30, 2020
Challenges in the development and exploitation of new therapeutic options targeting the histaminergic systemPaul L Chazot, Ekaterini Tiligada
Pharmacological Research|September 5, 2016
Ligand autoradiographical quantification of histamine H<sub>3</sub> receptor in human dementia with Lewy bodiesNatasha L Lethbridge, Paul L Chazot
American Journal of Physical Anthropology|October 7, 2020
Desperately seeking stress: A pilot study of cortisol in archaeological tooth structuresLeslie Quade, Paul L Chazot, Rebecca Gowland
Photobiomodulation, Photomedicine, and Laser Surgery|October 18, 2021
Effect of Transcranial Near-Infrared Light 1068 nm Upon Memory Performance in Aging Healthy Individuals: A Pilot StudyGordon Dougal, Abdel Ennaceur, Paul L Chazot
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Drug News & Perspectives|April 7, 2010
Therapeutic potential of histamine H3 receptor antagonists in dementiasPaul L Chazot
British Journal of Pharmacology|May 6, 2009
Advances in histamine pharmacology reveal new drug targetsPaul L Chazot
Current Medicinal Chemistry|February 18, 2004
The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologiesPaul L Chazot
Current Opinion in Investigational Drugs (London, England : 2000)|July 31, 2007
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndromePaul L Chazot
British Journal of Pharmacology|August 16, 2013
Histamine pharmacology: four years onPaul L Chazot
Pharmacology Research & Perspectives|April 13, 2016
Preclinical animal anxiety research - flaws and prejudicesAbdelkader Ennaceur, Paul L Chazot
British Journal of Pharmacology|January 30, 2020
Challenges in the development and exploitation of new therapeutic options targeting the histaminergic systemPaul L Chazot, Ekaterini Tiligada
Pharmacological Research|September 5, 2016
Ligand autoradiographical quantification of histamine H<sub>3</sub> receptor in human dementia with Lewy bodiesNatasha L Lethbridge, Paul L Chazot
American Journal of Physical Anthropology|October 7, 2020
Desperately seeking stress: A pilot study of cortisol in archaeological tooth structuresLeslie Quade, Paul L Chazot, Rebecca Gowland
Photobiomodulation, Photomedicine, and Laser Surgery|October 18, 2021
Effect of Transcranial Near-Infrared Light 1068 nm Upon Memory Performance in Aging Healthy Individuals: A Pilot StudyGordon Dougal, Abdel Ennaceur, Paul L Chazot
Pageof 6